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The Role of TNF in the 
Pathogenesis of Inflammatory 
Bowel Disease
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Abstract
Tumor necrosis factor (TNF) is a pleotropic cytokine involved in a wide range 
of pathological processes, including inflammatory bowel disease (IBD). In the past, 
TNF was recognized as a pro-inflammatory cytokine with deleterious effects. This 
has led to the development of anti-TNF drugs, which revolutionized the treatment 
of inflammatory disorders such as Crohn’s disease. However, in the past 20 years, 
clinical studies have shown that anti-TNF drugs are not always effective. Moreover, 
in some rare cases, anti-TNF drugs can even cause an aggravation of the disease. 
Nowadays, there is increasing evidence that TNF is not only detrimental but can 
also play an important role in health and the maintenance of homeostasis. The aim 
of this chapter is to briefly summarize the literature demonstrating the complex 
dichotomous role of TNF in IBD and discuss the role of anti-TNF drugs in the 
 treatment of IBD.
Keywords: tumor necrosis factor, inflammatory bowel disease, side effects, 
TNF inhibitors, paradoxical side effects, homeostasis
1. Introduction
Inflammatory bowel disease (IBD) is a chronic, relapsing inflammatory con-
dition of gastrointestinal tract with high incidence and prevalence in Western 
countries (North America, Europe, the highest in Scandinavia, and the United 
Kingdom) [1]. It is estimated that IBD affects 2.5–3 million people in Europe [2].
IBD consist primarily of Crohn’s disease (CD) and ulcerative colitis (UC), which 
are distinguished by the location and the nature of the inflammation [3]. Patients 
with IBD experience many symptoms, such as abdominal pain, fever, vomiting, 
diarrhea, rectal bleeding, anemia, and weight loss, which have significant impact 
on their quality of life. Symptoms vary depending on the location and severity of 
inflammation and can be very painful and disruptive and in some cases even life-
threatening (CD patients have 40% risk of mortality) [3].
IBD affects a young population, in the second and third decades of life or even 
in late adolescence [4]. The majority of patients with IBD progress to relapsing and 
chronic disease and need lifelong treatment and care. The health economic burden 
and permanent work disability in IBD are high in Europe with a total yearly direct 
healthcare cost of 4.6–5.6 billion Euros [2]. In recent years, the management of IBD 
has improved, due to the fact that the new treatments with anti-TNF drugs induce 
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not only clinical remission but also a significant endoscopic improvement or even 
disappearance of the intestinal lesions [5, 6].
However, in the past two decades, clinical studies have shown that anti-TNF 
drugs are not always effective. Moreover, in some rare cases, anti-TNF drugs can 
even cause an aggravation of the disease. Therefore, this chapter aims to briefly 
summarize the detrimental role of TNF in the pathogenesis of IBD and to highlight 
the beneficial role of TNF, which is too often overlooked in the health and the 
disease.
2. Dual identification of TNF (cachectin)
Tumor necrosis factor (TNF, also known as TNFa, cachectin, or cachexin) was 
identified/named in 1975 by Carswell et al. who demonstrated that the serum of 
endotoxin-treated mice, rat, and rabbits, previously infected with Mycobacterium 
bovis strain Bacillus Calmette-Guerin caused hemorrhagic necrosis of various 
tumors in mice. They found that hemorrhagic necrosis of tumors in vivo was 
caused by so-called tumor necrosis factor (TNF) released from host cells, very 
likely macrophages, in response to injected endotoxin. They showed that both, a 
TNF-positive serum and endotoxin, were effective in causing necrosis of similar 
spectrum of transplanted tumors and at a similar phase of their growth. Moreover, a 
TNF-positive serum had cytotoxic effects on mouse and human tumor cells in vitro 
as well [7].
In 1985, human TNF was purified, characterized, and cloned, which enabled 
production of large quantities of a highly purified TNF protein for extensive 
investigations [8, 9]. Since recombinant TNF has shown antitumor activity in both 
transplantable murine tumors and human tumor xenografts, TNF was quickly 
launched into clinical trials as a potential anticancer agent. Recombinant human 
TNF has been tested in several phase I and phase II clinical trials in the 1980s and 
1990s. However, the initial enthusiasm for the use of TNF as a systemic treatment 
has waned in the face of significant toxicities and a lack of evidence for therapeutic 
benefit. Systemic TNF treatment was found to cause dose-dependent toxicities such 
as fever, hypotension, and tachycardia [10–12].
Independently, other groups of researchers investigated metabolic basis 
for cachexia and endotoxin-induced septicemia and septic shock syndrome. 
Hypertriglyceridemia in animals injected with endotoxin was found to result from 
defective triglyceride clearance due to systemic suppression of the enzyme lipopro-
tein lipase. Finally, the substance responsible for specific suppression of lipoprotein 
lipase activity was identified and named cachectin [13, 14]. Interestingly, soon after 
the characterization of human TNF in 1985, it was recognized that the TNF and 
cachectin are the same single protein with the complex dual role [8, 9, 15].
Nevertheless, direct evidence that cachectin is a mediator of the pathology/
septicemia induced by endotoxin was demonstrated by Beutler and colleagues 
[16, 17]. They showed that passive immunization with rabbit antiserum or purified 
Ig against murine TNF protected the mice from the lethal effect of the endotoxin 
lipopolysaccharide [16]. The same group then showed that injection of recombi-
nant human TNF into rats in quantities similar to those produced endogenously in 
response to endotoxin caused hypotension, metabolic acidosis, hemoconcentration, 
and death of animals within minutes to hours. Thus, effects similar to those are 
induced by injection of endotoxin [17]. These observations led to the speculation 
that neutralization of TNF may be beneficial in life-threatening septicemia. Despite 
increased interest in the use of anti-TNF drugs for the treatment of sepsis, numer-
ous clinical trials have showed only a small survival benefit (3.6%) [18]. The likely 
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reason for the failure of anti-TNF drugs in sepsis can be found in the original animal 
study, where it was clearly demonstrated that neutralization of TNF was efficient in 
preventing death in mice only when administered before a very short time after the 
injection of endotoxin [16].
Nevertheless, the effort invested in the development of anti-TNF drugs, origi-
nally intended for the treatment of sepsis, enabled the use of anti-TNF therapy 
in the chronic inflammatory diseases, including IBD. However, the investigations 
and hopes regarding the use of anti-TNF drugs in sepsis and the use of TNF as an 
anticancer agent are still in progress [10, 19].
3. A link between TNF and IBD
The first evidence showing a link between TNF and IBD were publications 
reporting that patients with IBD have increased levels of TNF in serum, stool, or 
mucosal biopsy specimens [20–23]. However, the initial hopes for the use of TNF 
as a marker of IBD have waned when it was recognized that TNF can be increased 
also during infectious colitis [24] or TNF may even not be increased in patients with 
IBD [25] or TNF can be reduced in response to certain medication such as cyclo-
sporine A [22, 26]. Nevertheless, a published reports about successful treatment 
of CD patients with TNF chimeric monoclonal antibodies (cA2 or infliximab) [27] 
established clear association of TNF involvement in the pathogenesis of IBD and 
caused extensive investigation of TNF role in IBD and production of various genetic 
models, including transgenic mice with persistent TNF overproduction in various 
tissues.
It was clearly demonstrated that persistent systemic overproduction of TNF 
(TNF∆ARE/∆ARE mice) can cause severe systemic health problems in mice, such 
as severe chronic polyarthritis, profound inflammatory changes in the terminal 
ileum and occasionally in the proximal colon, hypoplastic thymus with atrophied 
and disorganized cortical and medullary areas, and occasional mild inflamma-
tion in the liver and lung. These alterations were first detected in homozygous 
mice between 1 and 4 weeks of their age. Heterozygous mice developed the same 
health problems but later in their life inflammatory arthritis at 6–8 weeks of age 
and severe inflammatory bowel disease extending into muscular layers of the 
bowel wall at 4–7 months of their age. Homozygous mice never exceeded the body 
weight of 3-week-old mice and died between 5 and 12 weeks of their age [28]. 
It was also demonstrated that chronic intestinal inflammation can be triggered 
by persistent local TNF overproduction. Mice homozygous for persistent over-
production of TNF in the intestinal epithelium (TNFi∆ARE/i∆ARE mice) developed 
chronic ileitis by the age of 16–20 weeks and had increased mucosal and systemic 
protein levels of TNF. No inflammation in other tissues was found. No histological 
signs of joint injury were observed. Heterozygous mice (TNFi∆ARE/+) develop only 
mild villous blunting with scarce inflammation (not significant) [29]. In addition, 
mice with persistent myeloid cell-specific TNF overproduction also developed 
symptoms of weight loss and ileitis by the age of 5 months (homo and hetero-
zygous) but with more severe symptoms in the homozygous mice. Interestingly, 
mice with persistent T lymphocyte-specific TNF overproduction developed mild 
symptoms of IBD but only on homozygous background. On the other hand, mice 
with persistent B lymphocyte-specific TNF overproduction did not show any 
signs of IBD by the age of 15 months [30]. Results of numerous animal studies 
gave tacit confirmation that persistent systemic or local TNF overproduction is 
detrimental and responsible for intestinal inflammation, serious health problems, 
and even death [31].
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The introduction of anti-TNF therapies in the 1998 affected the treatment of 
many chronic inflammatory disorders, including rheumatoid arthritis, ankylosing 
spondylitis, and IBD. Five therapeutic agents have been licensed in the USA and 
most other parts of the world. Randomized controlled trials demonstrated the 
efficacy and safety of induction and maintenance therapy for moderate-to-severe 
IBD. Subsequent studies have demonstrated that infliximab treatment results in 
a positive clinical response as well as in a significant endoscopic improvement, 
confirmed also by histological examination as a complete reduction in the inflam-
mation infiltrate. The breakthrough in the treatment of patients with IBD with 
anti-TNF therapy has firmly established the dogma that TNF is a major cytokine 
in this disease [32, 33]. Anti-TNF drugs such as infliximab, adalimumab, and 
etanercept are nowadays commonly used in the treatment of a variety of inflamma-
tory and autoimmune diseases (IBD, rheumatoid arthritis, psoriasis, psoriasiform 
arthritis, and ankylosing spondylitis). Nevertheless, with the increasing use and 
longer follow-up periods, more information about effectiveness and side effects of 
anti-TNF therapy in IBD has been published.
4. Side effects of anti-TNF drugs
First reported/known adverse events of anti-TNF drugs were mainly immunoge-
nicity leading to acute and delayed infusion reactions and loss of response, infec-
tious complication, and concerns about tumor induction or progression [34, 35].
Today, after two decades of clinical experience with anti-TNF drugs and 2 mil-
lion treated patients, it is widely known that around 30% of patients do not respond 
to anti-TNF therapy (primary nonresponders) and almost half of patients with 
initial response develop secondary loss of response within the first year. Among 
nonresponders, some may have low serum drug levels which could be explained by 
under-dosing or high drug clearance. Development of immunogenicity against the 
anti-TNF drugs is also associated with loss of response. In such cases, consideration 
of switch in anti-TNF drugs or dose escalation following loss of response may be an 
effective strategy [32]. However, some patients on anti-TNF drugs experience pri-
mary or secondary nonresponse despite adequate serum drug levels and the absence 
of neutralizing antibodies. Recently, it was proposed that such nonresponders may 
have upregulated other alternative inflammatory pathways independent of TNF 
[36]. Nevertheless, despite all complications and high costs of anti-TNF drugs, 
economic evaluation studies have shown that the benefit of anti-TNF drugs is still 
higher than the costs [37].
4.1 Anti-TNF drugs and risk of infection and malignancy
Susceptibility to infection and risk of malignancy has been a significant con-
cern from the beginning of anti-TNF drug use. In the past, it was widely reported 
that anti-TNF therapy was associated with increased susceptibility to infections, 
particularly tuberculosis and hepatitis B. However, when it was recognized that 
anti-TNF drugs trigger the reactivation of latent infections [38], screening for 
tuberculosis and hepatitis B in clinical settings was implemented. Soon, reports 
about tuberculosis or hepatitis infections associated with anti-TNF therapy dimin-
ished [34]. Interestingly, recent publications report that anti-TNF therapy alone 
does not increase the risk of serious infection in IBD patients [39, 40]. Moreover, 
a systematic review (5528 patients) reported that the rate of serious infection was 
significantly lower among pediatric patients with IBD treated with anti-TNF than 
those treated with steroids or adults with IBD who received anti-TNF therapy [39]. 
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In contrast, increasing number of reports about other untypical opportunistic 
infectious diseases, such as cytomegalovirus infection, histoplasmosis, aspergillosis 
appeared [34, 40]. Importantly, recent population-based study (190,694 patients 
with IBD) found that anti-TNF monotherapy was associated with increased risk 
of serious infection, mycobacterial infection, and bacterial infection but with 
decreased risk of opportunistic viral infection when compared with thiopurine 
monotherapy. However, when anti-TNF drugs are part of combination therapy with 
other immunosuppressive drugs, particularly thiopurines, the risk of serious infec-
tion and opportunistic infection increases [34, 41].
Anti-TNF drugs have been associated with the increased risk for malignancy [34]. 
In the past, few studies reported T-cell non-Hodgkin’s lymphoma or hepatosplenic 
T-cell lymphoma in IBD patients using anti-TNF drugs [42], while more recent studies 
found no association between anti-TNF drugs and hematologic malignancies. It was 
reported that the risk of lymphoma was no greater among children with IBD who 
received anti-TNF drugs than those treated with other IBD therapies or adults treated 
with anti-TNF drugs [39]. REFURBISH study found that the risk of T-cell non-Hodg-
kin’s lymphoma in IBD patients is increased with the use of combination anti-TNF 
and thiopurine therapy but not with the use of anti-TNF monotherapy [43]. However, 
recent cohort study of 189,289 patients with IBD reported that the use of thiopurine 
monotherapy or anti-TNF monotherapy in patients with IBD was associated with a 
small but statistically significant increased risk of lymphoma, and this risk was higher 
with combination therapy than with each of these treatments used alone [44].
4.2 Anti-TNF drugs and paradoxical side effects
Knowledge about immune diseases secondary to TNF target therapy is relatively 
new. Until 2007, altogether 233 cases of immune diseases secondary to TNF targeted 
therapy were reported [45]. Nowadays, increasing number of various paradoxical 
reactions is published such as psoriasiform skin lesions, uveitis, ileitis or colitis, 
joint manifestations, vasculitis and autoimmune disease (lupus and myositis), and 
sarcoidosis-like lesions. There are currently no predictors of their occurrence, and 
the optimal clinical management is still a matter of debate. Mostly paradoxical reac-
tions are poorly described, and their prevalence and pathogenesis are not known. 
Therefore, it is important to be aware of all possible side effects of TNF therapy to 
properly inform the patient about potential side effects of anti-TNF therapy before 
the treatment.
Psoriasis or psoriasiform skin lesions are one of the most frequently reported 
paradoxical reactions. Until November 2008, altogether 120 cases of psoriasis in 
patients treated with anti-TNF drugs were published. Among them 18 cases were 
found in patients with IBD (15%) [46]. Nowadays, increasing number of studies 
has shown that psoriasis can develop in IBD patients (adults or children) without 
any history of psoriasis and independent of the type of anti-TNF drugs [46–48]. 
However, in IBD patients with a history of psoriasis, anti-TNF treatment may trig-
ger reappearance (3/21) [47] or exacerbation of the psoriasis (2/18) [46, 48].
Retrospective cohort (917) reported that 29% patients undergoing anti-TNF 
therapy (infliximab) developed skin lesions such as psoriasiform eczema, xerosis 
cutis, palmoplantar pustulosis, and psoriasis. The average time from the start of 
TNF therapy to the onset of skin lesions varied from 14.3 weeks [46] to 2 years 
[46–48]. In most patients psoriatic lesions were effectively treated with topical 
steroids, and in patients with severe psoriasis or patients without response to topical 
therapy, anti-TNF therapy was discontinued [47]. In another study in almost half 
of patients changed their initial anti-TNF agent despite conventional skin-directed 
therapies, and one-third of patients discontinued all anti-TNF therapy [48].
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Lichenoid drug reaction in association with anti-TNF therapy was also reported. 
Until 2015, only seven cases were reported in association with anti-TNF drugs. Oral 
lichen planus occurred between 8 weeks and 6 months after anti-TNF therapy. 
Outcome was mainly favorable with improvement or recovery with or without 
cessation of the TNF blocker. Authors recommend a careful monitoring for oral 
manifestations in IBD patients treated with TNF inhibitors. OLP is thought to be 
mediated by dendritic cells and T cells [49].
Patients treated with anti-TNF therapy (i.e., etanercept, adalimumab, and 
infliximab) can develop sarcoidosis-like lesions. Until 2017, altogether 90 cases were 
reported, 6 cases in IBD patients. Median duration between initiation of anti-TNF 
therapy and diagnosis was 22.5 months (range 1–84 months). Most frequently 
affected organs were lungs, skin, and eyes [50].
Patients with IBD developed new onset arthritis or synovitis after 2.5 ± 1.6 years 
of successful anti-TNF treatment. The onset of paradoxical arthritis appeared when 
IBD patients were in clinical and endoscopic remission but with signs of histologi-
cally diagnosed subclinical inflammation. The inhibition of inflammatory pathways 
alternative to TNF (IL12/1L23) may be an effective therapeutic option for severe 
paradoxical articular manifestations [51].
The lupus-like syndrome can be observed in 0.5–1% of patients treated with 
anti-TNF drugs and appears independent of the type of anti-TNF drugs. Most 
patients develop fatigue or fever, musculoskeletal or skin symptoms, or serositis, 
a rarely major organ disease. The symptoms resolve after discontinuation of TNF 
therapy [52, 53].
5. The beneficial role of TNF
Soon after the identification of TNF and production of recombinant TNF, it was 
recognized that the biological effects of TNF may be both injurious and beneficial. 
TNF can have a direct cytostatic and cytotoxic effect on human tumor cells, as well 
as a variety of immunomodulatory effects on various immune effector cells, includ-
ing neutrophils, macrophages, and T cells. It can have a number of anti-infective 
and metabolic effects [54].
Today, in the era of anti-TNF drugs, the beneficial role of TNF is often in the 
shadow and is highlighted only after the appearance of a new adverse effect of anti-
TNF drugs in clinical use.
Experimental studies have shown that TNF has important role in maintain-
ing intestinal integrity [55]. If infection or injury occurs, TNF is rapidly released 
to promote the acute-phase inflammatory response (i.e., IL1, IL6-production of 
pro-inflammatory cytokine cascade) and to trigger the localized accumulation of 
leukocytes. Endothelial cells respond to TNF by releasing chemokines (IL-8, MCP-
1, IP-10) and adhesion molecules (E-selectin, ICAM-1, VCAM-1). Collectively, 
these solubles and cell surface molecules lead to the recruitment of distinct popula-
tions of leukocytes to sites of infection/injury to eliminate the initial cause of cell 
injury, clear out necrotic cells and tissues damaged from the original insult and the 
inflammatory process, and initiate tissue repair. Indirectly, TNF also contribute to 
increased local blood flow and vascular permeability and regulation of coagulation. 
TNF increases mediators such as prostaglandins and platelet-activating factor [56].
However, in case of chronic TNF deprivation, intestinal barrier is more sensi-
tive to infection and injury. Mice with TNF deprivation (caused by anti-TNF drugs 
or target mutations) failed to resist L. monocytogenes infections and died few days 
after the infection [57]. Mice deficient in TNF or TNFR1 are highly susceptible to 
Mycobacterium and Staphylococcus infection as well [54, 59]. It was found that TNF 
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deprivation caused delayed elimination of bacterium from the spleens and livers. 
However the effect was dose and time dependent. The worst results were observed 
when anti-TNF drug was given between days 0 and 2 of infection [57].
TNF has also important role in maintaining and protecting epithelial cells from 
toxic injury. For instance, DSS, a toxic agent that damages the intestinal epithelia, 
induce development of an acute inflammation in mice, which usually resolves in a 
few weeks. However, when mice have blocked production of TNF (induced by dele-
tion of TNF gene or anti-TNF drugs), the inflammation in the intestine becomes 
devastating and life-threatening [58].
All these studies demonstrate that homeostatic concentrations of TNF have 
important protective role against intestinal injury. However, homeostatic con-
centrations of TNF are also important for effective innate and adaptive immune 
responses. It was found that mice genetically deficient in TNF completely lack 
splenic primary B-cell follicles and cannot form organized follicular dendritic cell 
networks and germinal centers [59]. Thus, chronic TNF deprivation may cause 
disturbances in innate and adaptive immunity. TNF is an important regulator 
of macrophage function required to control infection and can also contribute 
to containment of the disease by promoting migration of immune cells and 
granuloma formation at sites of infection. In case of tuberculosis, an intracellular 
pathogen, formation of granulomas and walling off the bacteria by macrophages 
and T cell (central memory T cells (CCR7+CD27+) and effector memory T cells 
(CCR7−CD27−)), is thus one of the protective mechanisms to control tuberculosis 
infection. In latency, infection is contained in a nondividing state within mac-
rophages. However, anti-TNF therapy disturbs the physiological TNF-mediated 
immunoinflammatory responses and causes disease reactivation or dissemination 
seen in patients receiving TNF blockade [38].
It is interesting that increased susceptibility to infection and a slightly increased 
risk for malignancy have been expected side effects of anti-TNF drugs and have 
been confirmed in clinical practice. However, the observation that anti-TNF drug 
could lead to aggravation of preexisiting autoimmune diseases or onset of a new 
inflammatory diseases was not expected. Although numerous experimental stud-
ies have shown complex role of TNF in the innate and adaptive immunity [60], 
only paradoxical side effects of anti-TNF drugs clearly demonstrated that the 
maintenance of homeostatic TNF concentrations is important for normal function 
of organism. Recently, it was confirmed that paradoxical psoriasis is caused due 
to the TNF deprivation. Namely, in normal condition a production of type I IFN 
by plasmacytoid dendritic cells (pDC) is downregulated by TNF. In case of TNF 
deprivation (caused by anti-TNF drugs), production of IFN by pDC is not regulated 
anymore. The resulting type I interferon overexpression is responsible for the skin 
phenotype of paradoxical psoriasis, which, unlike classical psoriasis, is independent 
of T cells [61].
6. Conclusions
Although our understanding of TNF has increased considerably over the past 
two decades, novel finding is well in line with what had been predicted from 
previous mouse studies. However, the observation that anti-TNF drugs could lead 
to aggravation of preexisiting diseases or onset of a new inflammatory diseases 
was not expected. Nevertheless, paradoxical reaction appears independently of the 
underlying disease or the type of anti-TNF drugs used and regresses upon discon-
tinuation of therapy, which suggests that paradoxical reactions really are a side 
effect of TNF blockade and not de novo disease. Thus, paradoxical reactions can 
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once again remind us that TNF physiologically possess various beneficial roles, and 
thus the maintenance of homeostatic TNF concentrations is important for normal 
function of an organism.
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